UK markets open in 28 minutes
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • HANG SENG

    29,455.44
    -472.32 (-1.58%)
     
  • CRUDE OIL

    52.54
    -0.59 (-1.11%)
     
  • GOLD FUTURES

    1,861.20
    -4.70 (-0.25%)
     
  • DOW

    31,176.01
    -12.39 (-0.04%)
     
  • BTC-GBP

    22,895.18
    +629.48 (+2.83%)
     
  • CMC Crypto 200

    617.39
    +7.40 (+1.21%)
     
  • ^IXIC

    13,530.92
    0.00 (0.00%)
     
  • ^FTAS

    3,802.30
    -14.01 (-0.37%)
     

Shareholder Alert: Robbins LLP Announces Fortress Biotech, Inc. (FBIO) is Being Sued for Misleading Shareholders

·2-min read

Shareholder rights law firm Robbins LLP announces that a purchaser of Fortress Biotech, Inc. (NASDAQ: FBIO) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between December 11, 2019 and October 9, 2020. Fortress Biotech develops and commercializes pharmaceutical and biotechnology products.

If you suffered a loss due to Fortress Biotech, Inc.'s misconduct, click here.

Fortress Biotech, Inc. (FBIO) Misled Shareholders About the Viability of its Intravenous Tramadol Product

According to the complaint, in December 2019, Fortress Biotech's wholly owned subsidiary, Avenue Therapeutics, Inc., submitted a New Drug Application ("NDA") for its intravenous Tramadol product to the U.S. Food and Drug Administration ("FDA") for the management of moderate to moderately severe pain in adults in a medically supervised health care facility. During the class period, defendants made materially false and misleading statements regarding the viability of IV Tramadol by failing to disclose that IV Tramadol was not safe for the intended patient population, making it foreseeable that the FDA would not approve the NDA for IV Tramadol. On October 12, 2020, Avenue disclosed that it had received a Complete Response Letter from the FDA stating, "it cannot approve the application in its present form" because "IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population." On this news, Fortress Biotech's stock price fell $1.00 per share, or almost 24%, on October 12, 2020, and has yet to recover.

If you purchased Fortress Biotech, Inc. (FBIO) securities between December 11, 2019 and October 9, 2020, you have until January 26, 2021, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Fortress Biotech Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005541/en/

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com